Tags

Type your tag names separated by a space and hit enter

Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Med Microbiol Immunol. 2004 Nov; 193(4):173-80.MM

Abstract

Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.

Authors+Show Affiliations

Zentaris AG, Weismüllerstrasse 45, 60314 Frankfurt am Main, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

14513375

Citation

Sindermann, H, et al. "Miltefosine (Impavido): the First Oral Treatment Against Leishmaniasis." Medical Microbiology and Immunology, vol. 193, no. 4, 2004, pp. 173-80.
Sindermann H, Croft SL, Engel KR, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol. 2004;193(4):173-80.
Sindermann, H., Croft, S. L., Engel, K. R., Bommer, W., Eibl, H. J., Unger, C., & Engel, J. (2004). Miltefosine (Impavido): the first oral treatment against leishmaniasis. Medical Microbiology and Immunology, 193(4), 173-80.
Sindermann H, et al. Miltefosine (Impavido): the First Oral Treatment Against Leishmaniasis. Med Microbiol Immunol. 2004;193(4):173-80. PubMed PMID: 14513375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Miltefosine (Impavido): the first oral treatment against leishmaniasis. AU - Sindermann,H, AU - Croft,S L, AU - Engel,K R, AU - Bommer,W, AU - Eibl,H J, AU - Unger,C, AU - Engel,J, Y1 - 2003/09/26/ PY - 2003/04/17/received PY - 2003/9/27/pubmed PY - 2005/5/20/medline PY - 2003/9/27/entrez SP - 173 EP - 80 JF - Medical microbiology and immunology JO - Med Microbiol Immunol VL - 193 IS - 4 N2 - Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy. SN - 0300-8584 UR - https://www.unboundmedicine.com/medline/citation/14513375/Miltefosine__Impavido_:_the_first_oral_treatment_against_leishmaniasis_ L2 - https://dx.doi.org/10.1007/s00430-003-0201-2 DB - PRIME DP - Unbound Medicine ER -